Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M Simpson, Mark Hallett, Eric J Ashman, Cynthia L Comella, Mark W Green, Gary S Gronseth, Melissa J Armstrong, David Gloss, Sonja Potrebic, Joseph Jankovic, Barbara P Karp, Markus Naumann, Yuen T So, Stuart A Yablon, David M Simpson, Mark Hallett, Eric J Ashman, Cynthia L Comella, Mark W Green, Gary S Gronseth, Melissa J Armstrong, David Gloss, Sonja Potrebic, Joseph Jankovic, Barbara P Karp, Markus Naumann, Yuen T So, Stuart A Yablon
Abstract
Objective: To update the 2008 American Academy of Neurology (AAN) guidelines regarding botulinum neurotoxin for blepharospasm, cervical dystonia (CD), headache, and adult spasticity.
Methods: We searched the literature for relevant articles and classified them using 2004 AAN criteria.
Results and recommendations: Blepharospasm: OnabotulinumtoxinA (onaBoNT-A) and incobotulinumtoxinA (incoBoNT-A) are probably effective and should be considered (Level B). AbobotulinumtoxinA (aboBoNT-A) is possibly effective and may be considered (Level C). CD: AboBoNT-A and rimabotulinumtoxinB (rimaBoNT-B) are established as effective and should be offered (Level A), and onaBoNT-A and incoBoNT-A are probably effective and should be considered (Level B). Adult spasticity: AboBoNT-A, incoBoNT-A, and onaBoNT-A are established as effective and should be offered (Level A), and rimaBoNT-B is probably effective and should be considered (Level B), for upper limb spasticity. AboBoNT-A and onaBoNT-A are established as effective and should be offered (Level A) for lower-limb spasticity. Headache: OnaBoNT-A is established as effective and should be offered to increase headache-free days (Level A) and is probably effective and should be considered to improve health-related quality of life (Level B) in chronic migraine. OnaBoNT-A is established as ineffective and should not be offered for episodic migraine (Level A) and is probably ineffective for chronic tension-type headaches (Level B).
© 2016 American Academy of Neurology.
Source: PubMed